Technology | July 26, 2011 | Dave Fornell

FDA: Stop Using CardioGen-82 Due to Increased Radiation Exposure

Patients set off U.S. border radiation detectors

July 26, 2011 – The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals to stop using CardioGen-82 for cardiac positron emission tomography (PET) scans. The manufacturer, Bracco Diagnostics Inc., has decided to voluntarily recall CardioGen-82 this week after two patients set off radiation detectors at a U.S. border crossings due to strontium contamination.

It is the only FDA-approved generator-based PET myocardial perfusion agent. It uses a strontium (Sr)-82 generator to produce a rubidium (Rb)-82 radiotracer injection.

The FDA has received reports of two patients who underwent PET myocardial perfusion imaging scans with CardioGen-82 who had detectable levels of radiation several months after their PET scans. Both patients were crossing the border to/from the United States when radiation detectors identified radiation originating from the patients.

The radiation was found to originate from strontium (Sr-82 and Sr-85). A PET scan had been performed in each patient approximately two and four months earlier, respectively. Since Rb-82 has a half-life of 75 seconds and both patients reported that they had no other exposure to radioactive substances, the residual radiation is likely due to undetected strontium breakthrough.

The strontium isotope exposure may have originated from the myocardial perfusion imaging, said Alberto Spinazzi, M.D., senior vice president of global medical and regulatory affairs, Bracco Diagnostics, in a prepared statement from the company.  He said neither strontium-exposed patient suffered any acute health effects or required treatment. However, the long-term effects, if any, are not known.

The radiation exposure that a patient would typically receive from an injection of Rb-82 chloride (approximately 2.8 mSv) is generally less than that associated with other radiotracer cardiac diagnostic scans.  The radiation exposure that the two patients received due to strontium isotope exposure appears to substantially exceed that typically associated with CardioGen-82.  This assessment is based upon modeling performed by the Los Alamos National Laboratory.  This modeling suggests that the excessive radiation exposure (approximately 90 mSv) associated with the strontium isotopes appears similar to the amount of cumulative radiation exposure some patients receive during cardiac diagnostic evaluations with other radionuclides. 

Based on further investigation, the FDA determined that the current CardioGen-82 manufacturing procedures are not sufficient to ensure reliable performance of the generator used to produce the Rb-82 chloride injections. The FDA stated reliable generator performance is essential to help prevent strontium breakthrough from CardioGen-82 and to prevent patients from being exposed to excess radiation. FDA is also currently investigating the sufficiency of the testing procedures used to detect strontium breakthrough at the clinical sites that use CardioGen-82. 

The FDA recommends that healthcare professionals use alternatives to the CardioGen-82 generator when planning nuclear medicine cardiac scans. Patients who have any questions or concerns should talk to their healthcare professional. 

The FDA is continuing to work with the Nuclear Regulatory Commission and Bracco to determine the root cause for the increased radiation exposure detected in the two patients. The extent to which any additional patients may have received inadvertent radiation exposure is also under investigation. FDA plans to notify the public with updates.

The total number of patients who have received doses from CardioGen-82 generators with strontium breakthrough is currently unknown. CardioGen-82 was first cleared by the FDA in 1989.

Bracco said the strontium breakthrough can occur with CardioGen-82 and necessitates close attention to mandatory daily quality control testing to help minimize radiation risks to patients. The company is emphasizing to all CardioGen-82 users the importance of strict adherence to the instructions contained in the prescribing information for CardioGen-82 regarding mandatory daily strontium breakthrough testing (section 2.7 of the full prescribing information). The user training material for CardioGen-82 says testing for strontium breakthrough may sometimes need to be performed twice daily.

For more information: www.fda.gov/Drugs/DrugSafety/ucm265278.htm

 

 

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI. #SCCT #perfusionimaging 

Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI.

News | Computed Tomography (CT) | March 16, 2020
March 16, 2020 — The Society of Cardiovascular Computed Tomography (SCCT) released a new...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data

Figure 1: Depiction of the fully automated CT biomarkers tools used in this study. (A) Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data. (B) Case example in an asymptomatic 52-year-old man undergoing CT for colorectal cancer screening. At the time of CT screening, he had a body-mass index of 27·3 and Framingham risk score of 5% (low risk). However, several CT-based metabolic markers were indicative of underlying disease. Multivariate Cox model prediction based on these three CT-based results put the risk of cardiovascular event at 19% within 2 years, at 40% within 5 years, and at 67% within 10 years, and the risk of death at 4% within 2 years, 11% within 5 years, and 27% within 10 years. At longitudinal clinical follow-up, the patient suffered an acute myocardial infarction 3 years after this initial CT and died 12 years after CT at the age of 64 years. (C) Contrast-enhanced CT performed 7 months before death for minor trauma was interpreted as negative but does show significant progression of vascular calcification, visceral fat, and hepatic steatosis. HU=Hounsfield units.

News | Computed Tomography (CT) | March 06, 2020
March 6, 2020 — Researchers at the National Institutes of Health a
MR Solutions’ dry magnet MRI system for molecular imaging on display at EMIM 2020
News | Magnetic Resonance Imaging (MRI) | February 28, 2020
February 28, 2020 — MR Solutions will be displaying its la
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System

Potassium Molybdate Mo 99 Source Vessels for RadioGenix System (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | February 18, 2020
February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a
SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

News | Nuclear Imaging | February 14, 2020
February 14, 2020 —  ...